Click Links Down Below for our

NewsLetter for

the Week of 12/12/25

YouTube Video

Audio Podcast

Questors: Global Mental Health Summit Workshop Agenda

Dear New York State, New York City Government Leaders, Interested Citizens, and Media,

VIRTUAL MEETING ON DECEMBER 12th, 2025.

Please join us.  Our Mission is to SAVE LIVES. The NYS Ibogaine Research Bill Petition drive for the New York State Bipartisan Ibogaine Research Bill 1817 aims to bring ibogaine and psychedelics as mental health therapeutics by FDA clinical research for OUD//SUD for health equity for veterans and tribal opioid/substance response.  Your support is urgent for legalization through evidence based therapeutics research.  Ibogaine SAVE LIVES, as it has for many already.

Where:  Virtual Meeting Invite Questors: Global Mental Health Summit 2025

You are invited to a Zoom Virtual Meeting for Global Mental Health Summit

When: Friday, Dec 12, 2025 10:30 AM – 3:00 PM Eastern Time (US and Canada)

Register in advance for this meeting:

Topic: 10:30AM-3:00pm December 12^th, .2025

KRFI Questors Virtual Global Mental Health Summit Workshop
Time: Dec 12, 2025 10:15 AM – 3:00 PM Eastern Time (US and Canada)
Knowledge Recovery Institute Questors  is inviting you to a scheduled Zoom meeting.

Topic: 10:30AM-3pm 12.12.2025 KRFI Questors Virtual Global Mental Health Summit Workshop

Time: Dec 12, 2025 10:15 PM Eastern Time (US and Canada)

Join Zoom Meeting

https://us06web.zoom.us/j/5462756074?pwd=7BshATUBgODobKAVQRFo4vwo9PaA7m.1&omn=89081474999

View meeting insights with Zoom AI Companion

https://us06web.zoom.us/launch/edl?muid=af352cf5-3220-44f0-b10c-28d249748b7e

Meeting ID: 546 275 6074

Passcode: KRFI

After registering, you will receive a confirmation email containing information about joining the meeting.

When:  10:30 am to 3 pm EST Questors Segment 1-3

Virtual Questors: Global Mental Health Summit

Agenda

December 12th, Friday  

Opening Remarks and Keynote Speaker

*10:30 -11:30 AM  Moderated by Paul Sladkus, with MyungHi S. Lee, this session explores “Health Equity and Human Rights in Ibogaine access for Americans”, focusing on the evolving public–private sector partnership model supporting Ibogaine treatment for veterans and Indigenous and Tribal communities. A central theme is Access and Benefit Sharing (ABS) for Intellectual Property—an essential component in the future of Ibogaine and psychedelic-based therapeutics. The presentation highlights emerging global biodiversity initiatives, including the development of natural products extractive libraries that contribute to UN Convention on Biological Diversity (UNCBD)–aligned efforts in genomics, chemical data repositories, and carbon-sequestration-linked technologies. These initiatives support Indigenous-led entheogenic agricultural solutions and sustainable development protocols in the United States and across emerging market.

A key focus is KRFI’s Ibogaine IP shareholding model, designed to create royalty-based botanical drug pathways for tropical nations participating in Ibogaine and psychedelic research. This ABS-IP framework advances a sustainable public–private coordinating mechanism for long-term benefit sharing, capacity building, and in-country development. Use Case: Central America. The session will highlight the example of Costa Rica, featuring collaboration between national partners and the KRIBB Extractive Library. This includes the development of ABS-IP platforms for genomics and chemical data silos, private-sector registration pathways, and participation in the Forever Forest Program, which aims to support tropical nations in sustainable biodiversity management and equitable access to the economic benefits of natural products.

*11:30 -12:30 AM   “Technology & Innovation: AI, Social Responsibility & the American Ibogaine Initiative” This session will connect Andrew Romero InferenceFrame’s AI infrastructure with the policy and clinical mission of the American Ibogaine Initiative, with MyungHi S. Lee and KRFI Questors. Key discussion areas include:

* AI-enhanced investment frameworks for Ibogaine deployment

* Public–private partnership models supporting mental health reform

* Responsible funding strategies for bipartisan state-level Ibogaine bill

* Ethical scaling, oversight, and corporate social responsibility

* Building national infrastructure for Ibogaine-based mental health interventions

Together, the speakers outline how AI, biotechnology, and responsible investment can accelerate safe, equitable, and evidence-based Ibogaine access for veterans, Indigenous communities, and Americans facing mental health and addiction crises. Andrew Romero leads the development of high-reliability AI at InferenceFrame, where he designs and deploys advanced structured reasoning systems that strengthen decision-making in high-stakes environments. His work centers on Neuro-Symbolic (NeSy) approaches that integrate mathematical and logical reasoning, enabling AI systems to perform with greater precision and significantly reduced data requirements. InferenceFrame’s technology has been used to generate actionable insights for companies, investment funds, and research organizations, supported by strategic institutional funding. The company has also established cost-sensitive licensing agreements, allowing scalable access to its reasoning systems. These AI platforms demonstrate strong performance across diverse domains, including:

* Financial markets & capital allocation

* Robotics & autonomous system

* Mathematical and scientific discovery

* Risk assessment and high-stakes decision support

Andrew has also developed a suite of AI-driven investment banking tools, supporting capital structuring, due diligence, and near-automated deal execution. These technologies help reduce operational bottlenecks and increase accuracy in financial decision-making. InferenceFrame’s systems are adopted through partnerships with major FINRA-member firms, including GT Securities, where Andrew serves as Director.

* 12:30 – 2:30 PM  Moderated Paul Sladkus, and MyungHi S. Lee, with this session features collaborative framework for an Ibogaine Clinical R&D Alliance focused on FDA/MHRA/EMEA/ANVISA–registered clinical trial reporting and mechanism-of-action research.  The discussion highlights the KRFI Questors open-source clinical data platform, designed to address a persistent challenge in psychiatric research: fewer than 10% of clinical studies adequately assess double blinding integrity, as a foundational element of clinical trial design. With transparent, shared, and high-quality data, the field faces limitations in cost efficiency, reproducibility, and the ability to resolve the consequences of unblinding on data interpretation—issues that are especially critical for advancing Ibogaine and psychedelic-based mental health therapeutics.  The patient with placebo will experience withdrawal and possible unpredictable adverse reactions for the participants.

Questors aims to establish the Ibogaine & Psychedelic Clinical Evidence Assessment Working Group (I&P CEA-WG). As clinical programs grow in complexity—particularly those integrating psychotherapy with pharmacological interventions—KRFI is convening an  Ibogaine and Psychedelic Clinical Evidence Assessment Working Group (I & P CEA-WG). This online data review platform generates reporting by the research institutes with a parallel track on policy and legal advisory group conducted at the P Harvard Law School’s Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics,.  Independent Ibogaine and Psychedelic Clinical Evidence Assessment Working Group (I & PCEA-WG).works with parallel track with online CTMS with institutional partnership and safety and pharmacovigilance and technical platform to aid the institutions, practitioners, and research community.

Current State of the National Ibogaine Consortium endeavors by Bryan Hubbard and Rick Perry Co-founders of the Americans for Ibogaine and its role in a Public–Private Sector Partnership in Ibogaine Clinical Research.  The New York State Ibogaine Research Bill Action Plan for January 2026, This announcement aims to address the including:

* Upcoming NYS Senate hearings featuring Ibogaine testimonials

* Coordinated state-level action plans in NYS, Texas, Arizona, Ohio, and Colorado

* Responses from state authorities across the United States

Policy and Mental Health Strategy: The discussion will focus on mental health policy initiatives in New York State, exploring the allocation of $12 billion USD toward mental health and addiction programs. Special emphasis will be placed on the NYS Ibogaine Research Bill, led by Bipartisan Senate sponsors Natalie Rodriguez (D) and Jacob Ashby (R) during the January 2026 Hearing.

Speakers Biography

Andrew Romero is the Founder and Principal of InferenceFrame and a Director at GT Securities, where he serves as Managing Director for the Global Mental Health Security Fund. His work integrates investment banking with advanced data science and AI, particularly in the development of structured reasoning systems designed for reliability in high-stakes environments. Through InferenceFrame, Andrew has led the creation of AI and data-driven technologies that support situational reasoning, grounded in mathematical and logical frameworks and informed by a NeSy (Neuro-Symbolic) approach. These systems are engineered to deliver dependable performance while significantly reducing data requirements. InferenceFrame has provided insights and analytical solutions to numerous companies, investment funds, and research organizations, and has established cost-sensitive licensing agreements for its proprietary reasoning platforms. Strategic institutional funding has supported the continued development and demonstrable performance of these systems across diverse domains. Andrew’s work spans multiple application areas, including financial markets, robotics, and mathematical and scientific discovery, with a wide range of future use cases under exploration. In the investment banking domain, he has developed AI-driven solutions for capital structuring, due diligence, and near-automated deal execution. His technology is partnered with several leading FINRA-member firms, including GT Securities, where his expertise supports innovative financial solutions at the intersection of AI and global mental health strategy.

MyungHi S. Lee, DAOM, is the Founder and CEO of the Knowledge Recovery Foundation/Institute (KRFI), established in 1989 with a focus on global health challenges including malaria, tuberculosis, and HIV/AIDS. Under her leadership, KRFI has addressed major policy and implementation barriers related to Artemisinin Combination Therapy (ACT), contributing to advancements in artemisinin supply—such as the development of supercritical fluid extracts (SFE), high-yield cultivars, Drug Master Files (DMFs), and ACT clinical trials in Africa. Her collaborative work with Dr. Lee Sang Wook supported the WHO Secretary General’s Rollback Malaria initiative from 2004 to 2010, particularly in areas of ABS-IP policy and ACT deployment.  MyungHi is a Natural Products Pharmacognosist with specialized expertise in supercritical extraction technologies, prodrug formulation, and orally disintegrating tablet (ODT) manufacturing across the UK and Korea. She has more than 25 years of experience navigating regulatory compliance and has organized joint conferences with KSEA on GMP manufacturing, DSEA Act compliance, and FDA regulatory pathways for botanical drug development.  Currently, KRFI is expanding its work in Questors clinical trial management systems (CTMS) and reporting platforms for Ibogaine and psychedelics. KRFI’s CRO division, KRFI Questors, is dedicated to education in drug safety and pharmacovigilance, and actively supports the development of FDA clinical trials for Ibogaine targeting opioid and substance use disorders (OUD/SUD).

Presenter:  Reverend Paul Sladkus, All Faiths and Spiritual, Host of over 7,500 Good News Broadcast Programs, with over 1,000 on Health and Wellness.  Former Executive with CBS and PBS/Channel 13 TV.  Worked on the original Award Winning Brain Series for PBS. www.pausetheworldforpeace.org. THERE IS NO PEACE WHEN YOU ARE A DRUG ADDICT.

MyungHi Sonserai Lee DAOM

Knowledge Recovery Foundation/Institute
e:MyungHi.s.lee@krfi.org
t:917 913 4543; 212 722 3960
Www.KRFI.org
Www.krfi.org/psa
www.krfi.org/ press announcement
Www.KRFI.org/knowyourdrugs
www.krfi.org/NYS ibogaine bipartisan bill

When it comes to protein, most people think they need to reach for the steak or the chicken. The tasty truth bomb is plants can satiate your protein cravings, and more.

Raising animals for food is responsible for 14.5% of greenhouse gas emissions across the world and is expected to account for nearly half of global emissions by 2030. Livestock guzzles water, uses up land, and leaches pollutants into our air and water.

Not to mention, the way we treat farm animals is abhorrent. 90% of the world’s agricultural  animals are living in factory farms, confined in cramped, barren cages or pens that prevent basic natural behaviors. Every year, 100 billion animals are killed for their meat and other parts of their bodies. To make matters worse, roughly 84% of antibiotics given to factory-farmed animals are not used to treat illness, but to promote growth or prevent disease in overcrowded conditions. What is more, these practices are strongly linked to the rise of antibiotic-resistant “superbugs,” which were connected to 975,000 human deaths in 2019.

In contrast, plants like beans, lentils, tofu, and nuts are the quiet eco-heroes of your pantry, feeding your body and healing the Earth at the same time. All without animal cruelty. Here’s a lineup of 7 delicious, nutrient-packed, planet-friendly proteins ready to revolutionize your plate.

for more info, go to 7 Powerful Plant Proteins That Pack a Punch – Earth Day